EVAX Evaxion
Price Chart
Executive Summary
Evaxion announced new preclinical data for its off-the-shelf AML vaccine EVX-04, demonstrating complete expression in human cells, immune recognition/activation, and targeted cell-killing across diverse human immune profiles. The data will be presented at EHA 2026 Congress on June 13, 2026, and the company is preparing a regulatory filing for clinical testing. This is positive but early-stage, with no revenue or timeline to clinic.
Actionable Insight
Monitor the EHA 2026 poster presentation on June 13, 2026, for additional detail on immunogenicity and potential partner interest. The next catalyst is the regulatory filing for clinical testing — no date provided. Given the early stage, this is not a near-term revenue event; the stock may see modest trading interest around the EHA presentation.
Key Facts
- EVX-04 is an off-the-shelf therapeutic vaccine for acute myeloid leukemia developed using the AI-Immunology™ platform.
- Preclinical data shows EVX-04 is successfully expressed, secreted in human cells, and induces specific immune responses and targeted cell-killing.
- Data will be presented at the EHA 2026 Congress in Stockholm, Sweden on June 13, 2026.
- The company is preparing a regulatory filing to begin clinical testing, but no timeline for an IND/CTA or first-in-human study was provided.
- Evaxion is a clinical-stage TechBio company with a market cap of ~$32M and no disclosed revenue from approved products.
Financial Impact
No financial figures disclosed. The company is pre-revenue and at the preclinical stage for EVX-04.
Risk Factors
- EVX-04 is still at the preclinical stage; clinical failure risk remains high.
- Evaxion has a small market cap (~$32M) and may require additional capital to fund clinical development.
- AML treatment landscape is competitive with existing therapies and other vaccine approaches.
- No timeline for a regulatory filing was disclosed, creating uncertainty on the next catalyst.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310196 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
6-K
| $3.71 awaiting T+5 | awaiting T+5 | — | $3.64 (−1.89%) |
|
Jun 12, 2026
3d ago
|
Press Release
| $3.71 awaiting T+5 | awaiting T+5 | — | $3.64 (−1.89%) |
|
Jun 11, 2026
3d ago
|
6-K
| $3.72 awaiting T+5 | awaiting T+5 | — | $3.64 (−2.15%) |
|
Jun 11, 2026
4d ago
|
Press Release
| $3.72 awaiting T+5 | awaiting T+5 | — | $3.64 (−2.15%) |
|
May 12, 2026
4w ago
|
6-K
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.64 (−12.71%) |
|
May 12, 2026
4w ago
|
Press Release
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.64 (−12.71%) |
|
May 7, 2026
5w ago
|
6-K
| $4.07 $4.16 | ▲ +2.21% | ▲ +0.71% | $3.64 (−10.57%) |
|
May 4, 2026
5w ago
|
Press Release
| $4.57 $4.23 | ▼ −7.55% | ▼ −10.49% | $3.64 (−20.35%) |
|
Apr 27, 2026
6w ago
|
6-K
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.64 (−12.92%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.64 (−12.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access